Table 2.
Associations Between Changes in DCE-MRI and 18F-FDG PET Parameters and Pathologic Response.
| Tumor Measurements | Treatment Outcomes Residual Disease |
||
|---|---|---|---|
| pCR mean (SD) | mean (SD) | p* | |
| DCE-MRI | |||
| Δ Volume (%) | −97 (4) | −70 (24) | 0.060 |
| Δ SER (%) | −52 (7) | −17 (21) | 0.012 |
| Δ PE (%) | −81 (10) | −24 (24) | 0.004 |
| 18F-FDG PET | |||
| Δ K1 (%) | −83 (11) | −38 (39) | 0.029 |
| Δ Ki (%) | −97 (4) | −65 (28) | 0.019 |
*
Exact p-values for differences between patients with pCR (n=5) and those with residual disease (n=9) evaluated by Mann-Whitney U test.
Abbreviations: Δ = change after chemotherapy, DCE-MRI=dynamic contrast-enhanced MRI, SER = signal enhancement ratio, PE = peak enhancement, PET = positron emission tomography, pCR = pathologic complete response